Drug Research

 
Stock Quotes for Drug Research top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for 524689 investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for ankurdrugs investment picks

 
News Articles for Drug Research top ^
Covidien plc (NYSE:COV) today announced it has received CE Mark approval for its Stellarex™ drug-coated angioplasty balloon (DCB). The Stellarex™ DCB is used to restore and maintain blood flow to the arteries of the leg in patients with peripheral arterial disease (PAD). The Stellarex™ DCB is inserted into the diseased artery and inflated to open the vessel and restore blood flow, while a drug called paclitaxel is deposited onto the vessel wall to prevent the reoccurrence of new blockages.
Sign-up for Covidien’s Stellarex™ Drug-Coated Angioplasty Balloon Receives CE Mark to Treat Peripheral Arterial Disease Patients investment picks
2015/1/8
By Angela Chen The U.S. Food and Drug Administration isn't planning an advisory committee meeting at this time to evaluate Pfizer Inc.'s experimental breast-cancer treatment, despite the drug having received priority-review status in October, the company said Thursday.
Sign-up for Pfizer: FDA Not Planning Meeting Yet For Breast-Cancer Drug investment picks
By Erin McCarthy Sarepta Therapeutics Inc. said the U.S. Food and Drug Administration is requiring additional data for the new drug application for its Duchenne muscular dystrophy treatment eteplirsen.
Sign-up for Sarepta Therapeutics sees setback in Eteplirsen drug application investment picks
Geron Corp.'s stock (GERN) soared 35% in premarket trade Monday, after the company said the Food and Drug Administration lifted its hold on the investigational new drug application for its cancer treatment imetelstat.
Sign-up for Geron's stock soars after FDA lifts hold on new drug application investment picks
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, California, December 6-9, 2014, highlighting the following: “Antibody-drug conjugates represent an innovative and important therapeutic approach to targeting cancer.
Sign-up for Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C (HCV). The initial daclatasvir NDA submitted to the FDA focused on its use in combination with asunaprevir, an NS3/4A protease inhibitor.
Sign-up for Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.
Sign-up for ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola investment picks
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that data from pre-clinical studies of BP-100-1.01 (Liposomal Grb-2) were featured in the peer-reviewed journal Expert Opinion on Drug Delivery.
Sign-up for Bio-Path Holdings’ Liposomal Grb-2 Featured in Peer-Reviewed Journal “Expert Opinion on Drug Delivery” investment picks
FDA Not Currently Planning to Hold an Advisory Committee Meeting REDWOOD CITY, Calif., Jan.
Sign-up for Relypsa Announces Assignment of October 21, 2015 PDUFA Date for New Drug Application for Patiromer for Oral Suspension investment picks
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of KALYDECO ® (ivacaftor) in people with cystic fibrosis (CF) ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene.
Sign-up for U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced the U.S. Food and Drug Administration (FDA) has approved AbbVie’s VIEKIRA PAK™ (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) with or without ribavirin for the treatment of genotype 1 (GT1) patients with chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis.
Sign-up for Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus investment picks
- Significantly Expands AMRI's Analytical Services Capabilities and Extends Drug Product Development Services to include Sterile Injectable Formulation Development - ALBANY, N.Y. , Jan.
Sign-up for AMRI to Acquire Aptuit Drug Product Development and Aseptic Clinical Manufacturing Businesses investment picks
2015/1/12
The Food and Drug Administration plans to create a new Office of Pharmaceutical Quality to focus in part on manufacturing problems such as those that have beset generic companies that make extended-release versions of drugs.
Sign-up for FDA to Create New Drug Quality Office investment picks
2015/1/12
By Friedrich Geiger BERLIN--The U.S. Food and Drug Administration has paved the way for the production of additional drugs at a Fresenius SE (FRE.XE) plant in New York state after the authorities there had detected flaws at the facility some years ago, the German healthcare company said Monday.
Sign-up for FDA Allows Fresenius to Make New Drugs at Plant in US investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Drug Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Drug Related Products Stocks  |  Next: Drug Stores Shares